CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL

This trial tests a new type of CAR-T cell therapy — a treatment where your own immune cells are genetically modified to attack cancer — for patients with B-cell leukemia or B-cell lymphoma that has returned or stopped responding to other treatments. This particular CAR-T therapy targets two proteins on cancer cells (CD19 and BAFF). **You may be eligible if...** - You are 18 or older - You have been diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) or a type of B-cell non-Hodgkin's lymphoma (such as diffuse large B-cell lymphoma, follicular lymphoma, or mantle cell lymphoma) - Your cancer has relapsed (come back) or is refractory (stopped responding to treatment) - Your cancer cells test positive for CD19 **You may NOT be eligible if...** - Your cancer cells are CD19-negative - You have had very recent severe infection, uncontrolled organ failure, or other conditions making CAR-T therapy unsafe - You have active brain involvement by the cancer (in some cases) Talk to your doctor to see if this trial is right for you.